What is Kresladi and what disease does it treat?

Kresladi (marnetegragene autotemcel) is the first FDA-approved gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I), a rare and life-threatening inherited immunodeficiency. It is an autologous ex vivo lentiviral vector-based therapy that corrects the underlying genetic defect in a patient's own hematopoietic stem cells.

What GMP regulations apply to autologous gene therapies like Kresladi?

Autologous gene therapies are subject to 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals), 21 CFR Part 1271 (Human Cells, Tissues, and Cellular and Tissue-Based Products), and FDA's Office of Tissues and Advanced Therapies (OTAT) guidance documents. Chain of identity and chain of custody requirements are among the most critical compliance obligations for autologous CGT manufacturers.

What is a Pre-Approval Inspection (PAI) for a gene therapy product?

A Pre-Approval Inspection (PAI) is an FDA inspection of a manufacturing facility conducted before a BLA is approved. For gene therapy products, PAI investigators focus on process validation, chain of identity documentation, environmental monitoring, batch record completeness, analytical method validation, and comparability data across clinical and commercial manufacturing phases.

How does the RMAT designation benefit cell and gene therapy sponsors?

The Regenerative Medicine Advanced Therapy (RMAT) designation provides eligible CGT sponsors with early and intensive FDA interactions, including manufacturing-specific guidance from OTAT, eligibility for priority review, and potential for accelerated approval. It is specifically designed to help sponsors navigate the unique CMC and clinical complexities of regenerative medicine products.

Why is chain of identity so critical in autologous CGT manufacturing?

In autologous CGT manufacturing, every batch is derived from a single patient's cells and intended for administration back to that same patient. A chain of identity failure — losing the documented link between the patient and their specific batch at any point from apheresis through release — is considered a critical GMP deficiency by FDA and can result in a manufacturing hold, product recall, or patient safety event.

FDA Approves First Gene Therapy for Severe LAD-I

The U.S. Food and Drug Administration has approved Kresladi (marnetegragene autotemcel), marking a historic regulatory milestone as the first gene therapy approved for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). The approval, announced via the FDA's official press release, signals not only a breakthrough for patients with this rare and life-threatening condition, but also a meaningful inflection point for manufacturers, sponsors, and GMP consultants operating in the cell and gene therapy (CGT) space.

For organizations currently developing or manufacturing advanced therapy medicinal products (ATMPs) or CGTs, this approval is more than a headline — it's a compliance and strategy case study worth dissecting carefully.

What Is Leukocyte Adhesion Deficiency Type I (LAD-I)?

Leukocyte Adhesion Deficiency Type I is a rare, inherited primary immunodeficiency disorder caused by mutations in the ITGB2 gene, which encodes the CD18 protein — a critical component of beta-2 integrins. Without functional CD18, white blood cells cannot migrate from the bloodstream to sites of infection, leaving patients profoundly vulnerable to life-threatening bacterial and fungal infections.

Severe LAD-I, defined by CD18 expression of less than 2% of normal levels, is particularly devastating. Without hematopoietic stem cell transplantation (HSCT), severe LAD-I carries a mortality rate exceeding 60% within the first two years of life, according to published clinical literature. Even with allogeneic HSCT — the previous standard of care — outcomes are heavily dependent on donor match availability, and transplant-related morbidity remains significant.

This is the patient population Kresladi is designed to serve: pediatric patients with severe LAD-I who lack a matched related donor for HSCT.

What Is Kresladi (Marnetegragene Autotemcel)?

Kresladi is an autologous ex vivo lentiviral vector-based gene therapy. The manufacturing process involves:

Harvesting the patient's own hematopoietic stem and progenitor cells (HSPCs)
Transducing those cells ex vivo with a lentiviral vector carrying a functional copy of the ITGB2 gene
Reinfusing the corrected cells back into the patient following myeloablative conditioning

This autologous approach eliminates the dependency on a matched donor and, critically, removes the risk of graft-versus-host disease (GvHD) — one of the most serious complications of allogeneic HSCT.

Kresladi becomes only the twelfth gene therapy product approved by the FDA, joining a still-nascent but rapidly expanding class of transformative medicines that demand the highest level of GMP rigor throughout their manufacturing lifecycle.

GMP and Regulatory Implications: What Manufacturers Need to Know

This approval doesn't exist in a vacuum. For organizations in the CGT manufacturing space, each new product approval sets precedent — for CMC expectations, for process validation standards, and for what FDA reviewers will scrutinize during inspections. Here's what I see as the most critical compliance and operational implications:

1. Lentiviral Vector Manufacturing Is Under Intense Scrutiny

Kresladi relies on a lentiviral vector (LV) as its delivery mechanism. FDA's Office of Tissues and Advanced Therapies (OTAT) has repeatedly signaled, through guidance documents and 483 observations, that lentiviral vector manufacturing is one of the highest-risk unit operations in the entire CGT value chain. Key concerns include:

Replication-competent lentivirus (RCL) testing and release criteria
Vector copy number (VCN) control and distribution
In-process controls during transduction
Comparability of vector lots used across clinical phases

If your organization is producing or planning to produce LV-based CGTs, your process characterization data, comparability protocols, and release testing battery must be defensible before FDA. An inspection-ready state is not optional — it is the baseline expectation.

2. Autologous CGT GMP: Chain of Identity and Chain of Custody

Autologous therapies like Kresladi introduce manufacturing complexity that simply does not exist in conventional pharmaceutical or even allogeneic CGT manufacturing. Every single batch is patient-specific, which means:

Chain of identity (CoI) must be maintained from apheresis through release and administration
Chain of custody (CoC) documentation must be flawless and audit-trail-complete
Scheduling and logistics are clinical imperatives, not merely operational preferences

FDA's 21 CFR Part 211 and Part 1271 both apply here, and the intersection of those two regulatory frameworks creates compliance complexity that catches many sponsors off guard. I've seen manufacturers invest heavily in clinical development only to face manufacturing holds because their CoI SOPs couldn't withstand a pre-approval inspection (PAI).

3. Pre-Approval Inspection (PAI) Readiness for CGT Products

The approval of Kresladi reinforces that FDA will conduct rigorous PAIs for every novel CGT product. Based on my experience supporting CGT manufacturers through FDA inspections, the most common PAI deficiencies in this space include:

Deficiency Area	Frequency (Estimated)	Risk Level
Inadequate process validation / characterization	Very High	Critical
Chain of identity failures or gaps	High	Critical
Environmental monitoring gaps in classified suites	High	Major
Incomplete or inconsistent batch records	High	Major
Insufficient analytical method validation for release assays	Medium-High	Major
Comparability protocol deficiencies across sites or phases	Medium	Moderate
Training record deficiencies	Medium	Moderate
Incomplete change control history from Phase 1 to BLA	Medium	Major

Citation hook: FDA's Office of Tissues and Advanced Therapies has cited chain of identity failures as a critical GMP deficiency in autologous CGT pre-approval inspections, making end-to-end patient sample tracking a non-negotiable element of a compliant manufacturing system.

The lesson is clear: CGT sponsors cannot treat GMP compliance as a late-stage activity. By the time you're filing a BLA, your quality system, your batch records, your validation packages, and your facility controls need to have years of documented rigor behind them.

The Broader CGT Market Context: A Rapidly Maturing Regulatory Environment

The approval of Kresladi is part of a larger regulatory and commercial trend that compliance professionals must understand:

The global gene therapy market was valued at approximately $5.6 billion in 2023 and is projected to exceed $38 billion by 2030, representing a compound annual growth rate (CAGR) of roughly 31%, according to industry market research.
As of early 2025, FDA's OTAT had more than 4,000 active INDs in its portfolio, the vast majority of which involve gene therapy or cell-based products — a fourfold increase over the prior decade.
FDA has committed to approving 10–20 cell and gene therapy products per year by the mid-2020s, a target it articulated in its CGT action plan, signaling sustained regulatory bandwidth and prioritization in this space.

These figures aren't just market data — they represent a pipeline of products, sponsors, and manufacturing organizations that will all need to navigate the same GMP landscape that Kresladi's approval helps define.

Citation hook: With over 4,000 active CGT INDs at FDA and a projected market exceeding $38 billion by 2030, the cell and gene therapy sector represents the fastest-growing segment of FDA-regulated manufacturing — and among the most compliance-intensive.

What the Rare Disease Designation Pathway Tells Us

Kresladi almost certainly benefited from one or more expedited designation pathways — Orphan Drug Designation (ODD), Breakthrough Therapy Designation (BTD), and/or Accelerated Approval. LAD-I affects an estimated 1 in 100,000 to 1 in 300,000 live births, making it a textbook candidate for the rare disease regulatory toolkit.

For sponsors developing therapies for rare or ultra-rare conditions, this approval reinforces several strategic points:

Early engagement with FDA through Type B meetings is essential. Don't wait until Phase 3 to align on your primary endpoint, your comparability strategy, or your CMC package.
Surrogate endpoints may be acceptable, but they must be supported by robust analytical data and clinical plausibility arguments.
Post-marketing commitments are real obligations. Accelerated Approval, in particular, requires confirmatory evidence — and FDA has demonstrated renewed willingness to withdraw approvals when those commitments are not met.

Expedited Pathways: A Comparison for CGT Sponsors

Designation	Key Benefit	GMP/CMC Implication
Orphan Drug Designation	7-year market exclusivity, fee waivers	No direct CMC impact, but signals rare disease context
Breakthrough Therapy	Intensive FDA guidance, rolling review	Earlier CMC alignment meetings; higher FDA scrutiny of manufacturing
Accelerated Approval	Approval on surrogate endpoint	Post-marketing confirmatory study required; continued GMP oversight
RMAT (Regenerative Medicine Advanced Therapy)	Early interactions, priority review	CMC-specific guidance and manufacturing support from FDA
Priority Review	6-month review clock (vs. 12)	Compressed timelines increase pre-submission GMP readiness pressure

Manufacturing Scalability: The Hidden Compliance Challenge

One dimension of the Kresladi approval that doesn't make headlines but keeps CGT manufacturers up at night is manufacturing scalability. Autologous therapies are inherently difficult to scale because every batch is unique. As patient populations grow post-approval:

Slot availability for apheresis and manufacturing becomes a logistical bottleneck
Commercial-scale process validation must demonstrate equivalence to clinical-scale processes
Out-of-specification (OOS) investigations for patient-specific batches require SOPs that account for the unique nature of each starting material

Citation hook: Commercial-scale autologous CGT manufacturing requires validated processes that account for inherent patient-to-patient variability in starting material — a challenge that demands robust process characterization, not just a replicate confirmation strategy.

For companies preparing for a commercial launch in this space, I strongly recommend beginning technology transfer and scale-up risk assessments at Phase 2, not Phase 3. The time between IND and BLA in CGT development is simply not long enough to compress all of these activities into the final clinical phase.

What This Approval Means for Your Quality System Right Now

Whether you're a sponsor, a CDMO, or a clinical-stage manufacturer in the CGT space, here are the immediate actions I recommend in light of this approval and the regulatory trajectory it represents:

Audit your chain of identity SOPs. Can you trace every patient sample, every processing step, every release decision back to a unique patient identifier? If not, this is your highest-priority gap.
Review your LV vector release testing battery. Are your assays validated? Are your RCL testing methods aligned with current FDA expectations? Is your VCN distribution data part of your lot release package?
Assess your environmental monitoring program for classified manufacturing suites. CGT suites that handle open processing steps require rigorous EM programs under 21 CFR 211.42 and EU GMP Annex 1 (for dual-market products).
Pressure-test your batch record completeness. FDA PAI investigators will review batch records for every commercial-scale lot manufactured. Gaps, corrections without proper annotation, and missing in-process data are common 483 triggers.
Engage early with FDA on your CMC strategy. If you have an active IND for a CGT product, use your next Type B meeting to align explicitly on your process characterization expectations, your comparability protocol, and your planned validation approach.

At Certify Consulting, I've guided more than 200 clients through FDA-regulated compliance programs — many of them in the CGT and ATMP space. Our GMP consulting services for cell and gene therapy manufacturers are specifically designed to address the unique intersection of regulatory complexity and manufacturing innovation that products like Kresladi represent.

Expert Analysis: Why This Approval Is a Compliance Signal, Not Just a Headline

I want to be direct about something: every novel CGT approval is a data point about what FDA expects from manufacturers in this space. The clinical triumph of Kresladi — offering a potential cure to children who previously had almost no options — is real and meaningful. But for the manufacturing and quality community, the approval also means:

FDA reviewed and accepted a specific CMC package for a lentiviral vector-based autologous therapy
FDA conducted a PAI and found the manufacturing site acceptable
FDA's OTAT evaluated process validation, release testing, stability, and comparability data — and found it sufficient for approval

That is a competitive intelligence data point for every other CGT manufacturer. Study the product's BLA review documents when they become available in FDA's database. Understand the precedents being set. Use them to benchmark your own quality system.

The rare disease CGT space is evolving faster than any other segment of FDA-regulated manufacturing. Organizations that treat GMP compliance as a strategic asset — not a regulatory tax — are the ones that will reach approval efficiently. Those that don't are the ones I'm called in to help after a Form 483 or a Complete Response Letter.

Conclusion

The FDA's approval of Kresladi (marnetegragene autotemcel) for severe LAD-I is a landmark moment — for patients, for the rare disease community, and for the cell and gene therapy manufacturing sector. It validates the lentiviral vector-based autologous gene therapy platform, reinforces the importance of early and sustained GMP investment, and sets new expectations for what a CGT BLA package must demonstrate.

If your organization is in this space — at any stage — now is the time to assess your compliance posture honestly. The regulatory trajectory is clear. FDA is approving more CGT products, conducting more rigorous PAIs, and setting higher expectations with each new precedent.

Make sure your quality system is ready to meet them.

For guidance on CGT GMP compliance, pre-approval inspection readiness, or quality system development for advanced therapy products, visit thegmpconsultant.com or contact Certify Consulting directly.

Last updated: 2026-04-01